Empasiprubart significantly delayed IVIg retreatment and improved grip strength and patient-reported outcomes in both MMN cohorts.
Biomarker shifts, including reduced serum NfL levels, indicate axonal preservation and reinforce the neuroprotective potential of C2 inhibition.
At European Academy of Neurology (EAN) 2025, data from the Phase II ARDA study (NCT05225675) provided compelling proof-of-concept evidence for empasiprubart, a novel C2 complement inhibitor, in treating multifocal motor neuropathy (MMN). MMN is a chronic, immune-mediated neuropathy characterized by asymmetric limb weakness and axonal degeneration, with complement activation via the classic...
